Cargando…
Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma
Autores principales: | Ascione, Sophia, Harel, Stéphanie, Besson, Florent L., Belkhir, Rakiba, Henry, Julien, Royer, Bruno, Arnulf, Bertrand, Mariette, Xavier, Seror, Raphaèle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620568/ https://www.ncbi.nlm.nih.gov/pubmed/36951162 http://dx.doi.org/10.3324/haematol.2022.282214 |
Ejemplares similares
-
Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019) -
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls
por: Bitoun, Samuel, et al.
Publicado: (2021) -
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
por: Bitoun, Samuel, et al.
Publicado: (2022) -
The predictive value of serum myeloma protein in solitary plasmacytoma
por: Chang, Won Ick, et al.
Publicado: (2020) -
Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study
por: Seror, Raphaèle, et al.
Publicado: (2015)